Results 131 to 140 of about 739,113 (267)
ABSTRACT Background Factors associated with relapse course and disability in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) remain incompletely understood. Objectives To identify clinical and modifiable factors associated with relapse and disability in MOGAD. Methods In this ambispective multicentre cohort study using data from
Yingtao Wang +23 more
wiley +1 more source
Pathogens Know No Borders, Neither Should We - Exchange Programs for Surveillance Professionals. [PDF]
Karakök T, Raben D, Demirkol ME.
europepmc +1 more source
Advancing Stroke Clinical Trials Using Community Engagement and Implementation Science Approaches
ABSTRACT Stroke clinical trials are essential for advancing stroke care but can face challenges with recruitment, retention, clinical relevance, and translation into real‐world practice. We propose that integrating community engagement and implementation science approaches into stroke trials can help address these needs.
Lesli E. Skolarus +2 more
wiley +1 more source
Building sustainable public health data science and informatics capacity: possibilities for Eastern Europe and Central Asia. [PDF]
Gotsadze G +6 more
europepmc +1 more source
Characterizing Cutaneous α‐Synuclein Deposition and Seeding Activity in Parkinson's Disease Subtypes
ABSTRACT Objective Cutaneous phosphorylated α‐synuclein (p‐syn) and α‐synuclein seeding activity are promising biomarkers for Parkinson's disease (PD), but their clinical value remains uncertain due to disease heterogeneity. This study evaluates these two biomarkers in PD patients to inform phenotype‐specific diagnosis and disease severity assessment ...
Yuting Jin +8 more
wiley +1 more source
The Urban Mississippi: Valuing Connections in a Changing Climate
Emily Green, Bree Duever, and Amit Pradhananga
doaj +1 more source
Why does hepatitis B remain underprioritized? A view through lived experience. [PDF]
Ibrahim Y +10 more
europepmc +1 more source
ABSTRACT Objective To investigate which baseline clinical and imaging characteristics best predict TSPO‐PET‐measurable reduction in glial activation following treatment of multiple sclerosis (MS), to utilize this information for designing more efficient biomarker‐based clinical trials targeting glial activation.
Marlene T. Morch +5 more
wiley +1 more source

